

8. Literaturverzeichnis

1. Allendorf JD, Bessler M, Kayton ML et al. Increased tumor establishment and growth after laparotomy vs laparoscopy in a murine model. *Arch Surg* 1995;**130**:649-53.
2. Badia JM, Whawell SA, Scott-Coombes DM et al. Peritoneal and systemic cytokine response to laparotomy. *Br J Surg* 1996;**83**:347-8.
3. Baigrie RJ, Lamont PM, Kwiatkowski D et al. Systemic cytokine response after major surgery. *Br J Surg* 1992;**79**:757-60.
4. Baker DM, Jones JA, Nguyen-Van-Tam JS et al. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. *Br J Surg* 1994;**81**:1054-6.
5. Balague C, Braumann C, Fuhrer K et al. Validation of a new experimental model of colon cancer. *Surg Endosc* 2001;**15**:833-6.
6. Bedrosian I, Sofia RD, Wolff SM et al. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Cytokine* 1991;**3**:568-75.
7. Berenz T. Welche Perspektiven bietet Taurolidin in der Tumorthherapie? *Med Welt* 2003;**1-2**: 60.
8. Bonjer HJ, Gutt CN, Hubens G et al. Port site metastases in laparoscopic surgery. First workshop on experimental laparoscopic surgery, Frankfurt 1997. *Surg Endosc* 1998;**12**:1102-3.
9. Braumann C, Henke W, Jacobi CA et al. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. *Int J Cancer* 2004;**112**:225-30.
10. Braumann C, Ordemann J, Kilian M et al. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. *Clin Exp Metastasis* 2003;**20**:387-94.
11. Braumann C, Ordemann J, Wildbrett P et al. Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. *Clin Exp Metastasis* 2000;**18**:547-52.
12. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. *Cancer Res* 2001;**61**:6816-21.
13. Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. *Surg Oncol Clin N Am* 2001;**10**:655-77.

14. Castronovo V, Taraboletti G, Sobel ME. Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. *Cancer Res* 1991;**51**:5672-8.
15. Chen Z, Colon I, Ortiz N et al. Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. *Cancer Res* 1998;**58**:3668-76.
16. Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. *J Surg Res* 2001;**101**:111-9.
17. Da Costa ML, Redmond HP, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. *Surgery* 1998;**124**:516-25.
18. De Vita F, Orditura M, Lieto E et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. *Cancer* 2004;**100**:270-8.
19. Dofferhoff AS, Esselink MT, Vries-Hospers HG et al. The release of endotoxin from antibiotic-treated *Escherichia coli* and the production of tumour necrosis factor by human monocytes. *J Antimicrob Chemother* 1993;**31**:373-84.
20. Goldstein DS, Lu ML, Hattori T et al. Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery. *J Endourol* 1993;**7**:237-41.
21. Gorman SP, McCafferty DF, Woolfson AD et al. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. *J Appl Bacteriol* 1987;**62**:315-20.
22. Gutt CN, Hollander D, Brier CH et al. Influence of laparoscopy and laparotomy on systemic and peritoneal T lymphocytes in a rat model. *Int J Colorectal Dis* 2001;**16**:216-20.
23. Gutt CN, Kim ZG, Gessmann T et al. Hepatic tumor spread of colorectal cancer in a laparoscopic animal model. *Surg Endosc* 2000;**14**:448-51.
24. Gutt CN, Riemer V, Kim ZG et al. Impact of laparoscopic surgery on experimental hepatic metastases. *Br J Surg* 2001;**88**:371-5.
25. Hammer JH, Nielsen HJ, Moesgaard F et al. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. *Eur Surg Res* 1992;**24**:133-7.

26. Han Z, Ribbizi I, Pantazis P et al. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. *Anticancer Res* 2002;**22**:1959-64.
27. Hart H, Seifert J, Brendel W. Effects and side effects of taurolin in experimental peritonitis in the rat. *Langenbecks Arch Chir* 1986;**368**:149-62.
28. Hewett PJ, Texler ML, Anderson D et al. In vivo real-time analysis of intraperitoneal radiolabeled tumor cell movement during laparoscopy. *Dis Colon Rectum* 1999;**42**:868-75.
29. Iwanaka T, Arya G, Ziegler MM. Mechanism and prevention of port-site tumor recurrence after laparoscopy in a murine model. *J Pediatr Surg* 1998;**33**:457-61.
30. Jacobi CA, Bonjer HJ, Puttick MI et al. Oncologic implications of laparoscopic and open surgery. *Surg Endosc* 2002;**16**:441-5.
31. Jacobi CA, Menenakos C, Braumann C. Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. *Anticancer Drugs* 2005;**16**:917-21.
32. Jacobi CA, Ordemann J, Bohm B et al. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. *Am J Surg* 1997;**174**:359-63.
33. Jacobi CA, Peter FJ, Wenger FA et al. New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. *Dig Surg* 1999;**16**:393-9.
34. Jacobi CA, Sabat R, Ordemann J et al. Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model. *Langenbecks Arch Chir* 1997;**382**:S31-S36.
35. Jacobi CA, Wildbrett P, Volk T et al. Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth and implantation with laparoscopic surgery in a rat model. *Surg Endosc* 1999;**13**:1021-5.
36. Jurewitsch B, Jeejeebhoy KN. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. *Clin Nutr* 2005;**24**:462-5.
37. Kaidi AA, Nazzal M, Gurchumelidze T et al. Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation. *Am Surg* 1995;**61**:569-72.
38. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. *Cancer* 1994;**73**:2013-26.
39. Kilian M, Mautsch I, Braumann C et al. Effects of taurolidine and octreotide on tumor growth and lipid peroxidation after staging-laparoscopy in ductal pancreatic cancer. *Prostaglandins Leukot Essent Fatty Acids* 2003;**69**:261-7.

40. Knight BI, Skellern GG, Browne MK et al. Peritoneal absorption of the antibacterial and antiendotoxin taurodin in peritonitis. *Br J Clin Pharmacol* 1981;**12**:695-9.
41. Kolch W, Martiny-Baron G, Kieser A et al. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. *Breast Cancer Res Treat* 1995;**36**:139-55.
42. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. *Int J Antimicrob Agents* 2004;**24**:491-5.
43. Lanfrancone L, Boraschi D, Ghiara P et al. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. *Blood* 1992;**80**:2835-42.
44. Lee SW, Whelan RL, Southall JC et al. Abdominal wound tumor recurrence after open and laparoscopic-assisted splenectomy in a murine model. *Dis Colon Rectum* 1998;**41**:824-31.
45. Little D, Regan M, Keane RM et al. Perioperative immune modulation. *Surgery* 1993;**114**:87-91.
46. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* 1995;**146**:3-15.
47. Mathew G, Watson DI, Rofe AM et al. Wound metastases following laparoscopic and open surgery for abdominal cancer in a rat model. *Br J Surg* 1996;**83**:1087-90.
48. McCourt M, Wang JH, Sookhai S et al. Taurolidine inhibits tumor cell growth in vitro and in vivo. *Ann Surg Oncol* 2000;**7**:685-91.
49. Monson JR, Ramsey PS, Donohue JH. Taurolidine as an anti-neoplastic agent: a previously undiscovered role? *Br J Surg* 1990;**77**:1432.
50. Monson JR, Ramsey PS, Donohue JH. Taurolidine inhibits tumour necrosis factor (TNF) toxicity--new evidence of TNF and endotoxin synergy. *Eur J Surg Oncol* 1993;**19**:226-31.
51. Myers E, Allwood MC, Gidley MJ et al. The relationship between structure and activity of taurodin. *J Appl Bacteriol* 1980;**48**:89-96.
52. Neuhaus SJ, Watson DI, Ellis T et al. Efficacy of cytotoxic agents for the prevention of laparoscopic port-site metastases. *Arch Surg* 1998;**133**:762-6.
53. Neuhaus SJ, Watson DI, Ellis T et al. Influence of cytotoxic agents on intraperitoneal tumor implantation after laparoscopy. *Dis Colon Rectum* 1999;**42**:10-5.

54. Norrby K. Angiogenesis: new aspects relating to its initiation and control. *APMIS* 1997;**105**:417-37.
55. Opitz I, Veen HC, Braumann C et al. The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat model. *Surg Endosc* 2003;**17**:1098-104
56. Petrovic L, Schlegel KA, Ries J et al. In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. *Mund Kiefer Gesichtschir* 2003;**7**:102-7.
57. Pfirrmann RW. Übersicht - Taurolin bei schweren chirurgischen Infektionen. *Chirurgische Gastroenterologie mit interdisziplinären Gesprächen* 1991;131-42.
58. Pfirrmann RW. Pharmakologische Grundlagen. In: Jacobi C.A., ed. Taurolidin in der Tumorthherapie - Vorstellung eines neuen Therapiekonzeptes. *Uni-Med*, 2003:16-25.
59. Pfirrmann RW, Leslie GB. The anti-endotoxin activity of Taurolin in experimental animals. *J Appl Bacteriol* 1979;**46**:97-102.
60. Pidgeon GP, Harmey JH, Kay E et al. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. *Br J Cancer* 1999;**81**:1311-7.
61. Pollmann C, Huang X, Mall J et al. The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells. *Cancer Res* 2001;**61**:8416-21.
62. Redmond HP, Leahy AL, Carey JA et al. Beneficial effects of taurolidine in experimental pancreatitis. *J Surg Res* 1994;**56**:256-60.
63. Reinmuth N, Parikh AA, Ahmad SA et al. Biology of angiogenesis in tumors of the gastrointestinal tract. *Microsc Res Tech* 2003;**60**:199-207.
64. Ribizzi I, Darnowski JW, Goulette FA et al. Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. *Bone Marrow Transplant* 2002;**29**:313-9.
65. Rosman C, Westerveld GJ, Kooi K et al. Local treatment of generalised peritonitis in rats; effects on bacteria, endotoxin and mortality. *Eur J Surg* 1999;**165**:1072-9.
66. Rosman C, Westerveld GJ, van Oeveren W et al. Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. *Eur Surg Res* 1996;**28**:351-60.
67. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. *Science* 1987;**238**:491-7.

68. Schwartz SA, Hernandez A, Mark EB. The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. *Surg Oncol* 1999;**8**:143-53.
69. See WA, Chapman PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. *J Urol* 1987;**138**:182-6.
70. Shraye DP, Lukoff H, King T et al. The effect of Taurolidine on adherent and floating subpopulations of melanoma cells. *Anticancer Drugs* 2003;**14**:295-303.
71. Staubach KH. Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation. *Langenbecks Arch Chir* 1997;**382**:S26-S30.
72. Stendel R, Picht T, Schilling A et al. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. *Anticancer Res* 2004;**24**:1143-7.
73. Stendel R, Scheurer L, Stoltenburg-Didinger G et al. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. *Anticancer Res* 2003;**23**:2309-14.
74. Stendel R, Stoltenburg-Didinger G, Al Keikh CL et al. The effect of taurolidine on brain tumor cells. *Anticancer Res* 2002;**22**:809-14.
75. Stuntz M, Wilmoth G, Ong J et al. Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. *Dis Colon Rectum* 1997;**40**:1085-8.
76. Torisu H, Ono M, Kiryu H et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. *Int J Cancer* 2000;**85**:182-8.
77. Treutner KH, Bertram P, Lerch MM et al. Prevention of postoperative adhesions by single intraperitoneal medication. *J Surg Res* 1995;**59**:764-71.
78. Van Antwerp DJ, Martin SJ, Verma IM et al.. Inhibition of TNF-induced apoptosis by NF-kappa B. *Trends Cell Biol* 1998;**8**:107-11.
79. van den Tol PM, van Rossen EE, van Eijck CH et al. Reduction of peritoneal trauma by using nonsurgical gauze leads to less implantation metastasis of spilled tumor cells. *Ann Surg* 1998;**227**:242-8.
80. Volz J, Volz-Koster S, Kanis S et al. Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model. *Cancer* 2000;**89**:262-6.
81. Watson RW, Redmond HP, Mc CJ et al. Taurolidine, an antilipoplysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. *J Leukoc Biol* 1995;**58**:299-306.

82. Weberschock TB, Kirsch SK, Jacobi CA et al. Experimental application of taurolidine prevents metastatic tumor spread. *4th International Conference Of Experimental Laparoscopy* 2000, Berlin, Germany
83. Wenger FA, Kilian M, Braumann C et al. Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer. *Clin Exp Metastasis* 2002;**19**:169-73.
84. Whelan RL, Allendorf JD, Gutt CN et al. General oncologic effects of the laparoscopic surgical approach. *Surg Endosc* 1998;**12**:1092-5.
85. Wong CW, Lee A, Shientag L et al. Apoptosis: an early event in metastatic inefficiency. *Cancer Res* 2001;**61**:333-8.
86. Wordemann M, Fandrey J, Jelkmann W. Tumor necrosis factor-alpha production by human hepatoma cell lines is resistant to drugs that are inhibitory to macrophages. *J Interferon Cytokine Res* 1998;**18**:1069-75.
87. Wu JS, Pfister SM, Ruiz MB et al. Local treatment of abdominal wound reduces tumor implantation. *J Surg Oncol* 1998;**69**:9-13.
88. Yanagisawa M, Imai H, Fukushima Y et al. Effects of tumour necrosis factor alpha and interleukin 1 beta on the proliferation of cultured glomerular epithelial cells. *Virchows Arch* 1994;**424**:581-6.